Compare · INGM vs WGS
INGM vs WGS
Side-by-side comparison of Ingram Micro Holding Corporation (INGM) and GeneDx Holdings Corp. (WGS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INGM and WGS operate in Retail: Computer Software & Peripheral Equipment (Technology), so they compete in similar markets.
- INGM is the larger of the two at $6.37B, about 2.5x WGS ($2.53B).
- WGS has been more active in the news (5 items in the past 4 weeks vs 3 for INGM).
- INGM has more recent analyst coverage (23 ratings vs 8 for WGS).
- Company
- Ingram Micro Holding Corporation
- GeneDx Holdings Corp.
- Price
- $27.64-2.16%
- $85.19+0.34%
- Market cap
- $6.37B
- $2.53B
- 1M return
- -
- +25.30%
- 1Y return
- -
- -33.59%
- Industry
- Retail: Computer Software & Peripheral Equipment
- Retail: Computer Software & Peripheral Equipment
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- 2020
- News (4w)
- 3
- 5
- Recent ratings
- 23
- 8
Latest INGM
- Deutsche Bank initiated coverage on Ingram Micro Holding Corp. with a new price target
- Ingram Micro to Host 2026 Capital Markets Day on September 15, 2026 – Registration Now Open
- Amendment: SEC Form SCHEDULE 13G/A filed by Ingram Micro Holding Corporation
- Ingram Micro Accelerates AI Adoption Across the Global Channel with New Xvantage Integration Hub and MCP Server
- Ingram Micro Releases 2025 Sustainable Impact Report
- SEC Form 10-Q filed by Ingram Micro Holding Corporation
- Ingram Micro Holding Corporation filed SEC Form 8-K: Results of Operations and Financial Condition
- Ingram Micro Reports Record Q2 2026 Results Exceeding the High End of Guidance Across All Financial Metrics with Significant Operating Leverage
- Ingram Micro to Report Second Quarter 2026 Financial Results on July 30, 2026
- Large owner Platinum Equity, Llc sold $150,000,013 worth of shares (5,167,069 units at $29.03) (SEC Form 4)
Latest WGS
- SEC Form 144 filed by GeneDx Holdings Corp.
- GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
- GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s
- SEC Form SCHEDULE 13G filed by GeneDx Holdings Corp.
- GeneDx Launches New Online Offering for Families to Improve Accessibility of Exome Testing for Children with Global Developmental Delay, Intellectual Disability and Epilepsy
- Amendment: SEC Form SCHEDULE 13G/A filed by GeneDx Holdings Corp.
- GeneDx to Participate in Upcoming Investor Conferences
- SEC Form 10-Q filed by GeneDx Holdings Corp.
- GeneDx Holdings Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- GeneDx Reports Second Quarter 2026 Financial Results